EMEA-002727-PIP01-19-M01

Table of contents

Key facts

Active substance
  • nivolumab
  • Relatlimab
Therapeutic area
Oncology
Decision number
P/0070/2021
PIP number
EMEA-002727-PIP01-19-M01
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of melanoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Bristol-Myers Squibb International Corporation

E-mail: medical.information@bms.com
Tel. +44 1423 533 610

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating